These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16534038)

  • 1. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
    Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
    Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
    Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
    AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
    Trotta MP; Cozzi-Lepri A; Ammassari A; Vecchiet J; Cassola G; Caramello P; Vullo V; Soscia F; Chiodera A; Ladisa N; Abeli C; Cauda R; Buonuomi AR; Antinori A; d'Arminio Monforte A;
    Clin Infect Dis; 2010 Aug; 51(4):456-64. PubMed ID: 20597690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
    Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
    Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
    Chaiwarith R; Wachirakaphan C; Kotarathititum W; Praparatanaphan J; Sirisanthana T; Supparatpinyo K
    Int J Infect Dis; 2007 Sep; 11(5):413-6. PubMed ID: 17331776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.
    Reekie J; Mocroft A; Ledergerber B; Beniowski M; Clotet B; van Lunzen J; Chiesi A; Pradier C; Machala L; Lundgren JD;
    HIV Med; 2010 Aug; 11(7):469-78. PubMed ID: 20201975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
    Smith CJ; Phillips AN; Youle MS; Sabin CA; Lampe FC; Tsintas R; Tyrer M; Johnson MA
    HIV Med; 2007 Jan; 8(1):55-63. PubMed ID: 17305933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
    Alvarez-Uria G; Naik PK; Pakam R; Midde M
    Trop Med Int Health; 2012 Sep; 17(9):1152-5. PubMed ID: 22487689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.